Managing the Most Common GLP-1 Side Effects
Nausea, diarrhea, vomiting, and constipation are the most common effects of semaglutide and tirzepatide. Here is what the trial evidence shows, and the practical steps experts recommend.
If you have started a GLP-1 medication like semaglutide (Wegovy) or tirzepatide (Zepbound), or you are thinking about it, you have probably heard about the stomach troubles. Nausea, diarrhea, vomiting, and constipation are by far the most common side effects of these drugs. The good news, based on the trials that led to their approval, is that these symptoms are usually mild to moderate, tend to show up early, and often fade with time. This article explains what the evidence shows and the practical steps that experts recommend for managing the most common effects.
How common are these side effects?
Gastrointestinal (GI) symptoms are the signature side effects of GLP-1 medications, and they happen far more often than with a placebo. In a pooled analysis of the STEP 1-3 obesity trials, once-weekly semaglutide 2.4 mg was associated with nausea in about 44% of participants (versus 16% on placebo), diarrhea in about 30% (versus 16%), vomiting in about 25% (versus 6%), and constipation in about 24% (versus 11%). The FDA label for Wegovy lists these same four as the most common adverse reactions.
Tirzepatide follows a similar pattern, though the reported numbers tend to be somewhat lower. Its FDA label (Zepbound) lists nausea in roughly 25-29% of people, diarrhea in about 19-23%, constipation in about 11-17%, and vomiting in about 8-13%. In the SURMOUNT-1 obesity trial, GI symptoms were the most common adverse events and were mostly mild to moderate.
One important caveat: these figures come chiefly from obesity trials and drug labels. Reported rates vary by drug, dose, and the population studied, so they should not be treated as universal across every GLP-1 product or use.
Usually mild and temporary
The headline percentages can sound alarming, but the character of these symptoms matters as much as their frequency. In the pooled semaglutide analysis, 98.1% of the GI events were mild to moderate, transient, and occurred most often during or shortly after dose increases. The same held for tirzepatide: across the SURMOUNT-1 to -4 trials, GI events were mostly mild to moderate, appeared primarily during dose escalation, diminished over time, and rarely caused people to stop treatment.
That last point is worth underlining. In SURMOUNT-1, adverse events led to stopping treatment in 4.3%, 7.1%, and 6.2% of participants on the 5-, 10-, and 15-mg doses, compared with 2.6% on placebo. In other words, although GI symptoms were common, most people did not quit because of them.
Do these drugs work by making you sick?
A common belief is that GLP-1 medications cause weight loss mainly by making people nauseated and unable to eat. The trial evidence does not support that idea. In the semaglutide pooled analysis, a mediation analysis found that GI events explained less than one percentage point of the extra weight loss compared with placebo. For tirzepatide, weight reduction was similar among people who reported these GI symptoms and those who did not, and mediation analyses attributed less than 6% of the overall weight-loss difference to GI events.
The trials suggest these medications do not work chiefly by making you sick: side effects account for at most a small slice of the weight change.
It is fair to be cautious here, because these conclusions rest on statistical modeling rather than direct experiment. Still, the finding is consistent across both semaglutide and tirzepatide, which makes it a reasonably robust and reportable point.
Start low, go slow: managing the symptoms
The single most important tool for limiting side effects is built into how these drugs are prescribed: a gradual dose increase. The Wegovy label mandates a 16-week titration, starting at 0.25 mg weekly and stepping up through 0.5, 1, and 1.7 mg before reaching the 2.4 mg maintenance dose in week 17. Zepbound starts at a 2.5 mg initiation dose for four weeks, then rises in 2.5 mg steps, no sooner than every four weeks, toward a maintenance dose of 5, 10, or 15 mg. Both labels state that this schedule exists specifically to reduce GI side effects.
The labels also build in flexibility. If a patient does not tolerate a dose during escalation, the Wegovy label says clinicians should consider delaying the next increase by four weeks; if the 2.4 mg maintenance dose is not tolerated, it may be temporarily reduced to 1.7 mg. The Zepbound label similarly advises considering a lower maintenance dose if the current one is not tolerated. A multidisciplinary expert consensus echoes this 'start low, go slow' philosophy: extend the escalation phase by two to four weeks or pause it if nausea appears, and do not rule out reducing the dose if symptoms worsen.
Beyond dosing, expert consensus and dietary reviews offer practical everyday measures. For nausea, the suggestions include:
- Eat smaller, more frequent meals, slowly, and stop when you feel full
- Choose bland, low-fat foods and use simple cooking methods like steaming, baking, or boiling
- Try ginger
- Avoid fatty, fried, heavily seasoned, or spicy foods, strong odors, and alcohol
- Avoid lying down or doing vigorous activity right after eating
For constipation, the consensus advice is to get adequate fiber, drink generous amounts of sugar-free fluids, increase physical activity, and consider stool softeners. General dietary guidance also suggests staying hydrated by sipping water rather than drinking large volumes during meals, and adjusting fiber intake to your symptoms. Medications such as antiemetics for nausea or antidiarrheals are generally reserved for persistent cases. These specific pharmacologic suggestions come from expert consensus and review articles, not head-to-head trials, so any particular medicine should be decided with a clinician, not self-prescribed.
When to seek medical help
The symptoms described here are the common, usually self-limited ones. GLP-1 medications also carry rarer but serious risks, including pancreatitis, gallbladder disease, and bowel obstruction (ileus), along with a boxed warning about thyroid C-cell tumors. Severe, persistent, or unusual symptoms are not something to manage with diet tweaks alone; they warrant prompt medical attention. If you are unsure whether what you are feeling is routine or a warning sign, contact your healthcare provider.
- 01 Wharton et al., Diabetes, Obesity and Metabolism, 2022 pubmed.ncbi.nlm.nih.gov ↗Pooled STEP 1-3 GI tolerability analysis of once-weekly semaglutide 2.4 mg.
- 02 FDA Prescribing Information, WEGOVY (semaglutide) injection, 2024 dailymed.nlm.nih.gov ↗FDA label detailing the 16-week titration and most common adverse reactions (via DailyMed/NIH).
- 03 FDA Prescribing Information, ZEPBOUND (tirzepatide) injection, 2025 dailymed.nlm.nih.gov ↗FDA label detailing tirzepatide dose escalation and common adverse reactions (via DailyMed/NIH).
- 04 Jastreboff et al. (SURMOUNT-1), New England Journal of Medicine, 2022 pubmed.ncbi.nlm.nih.gov ↗72-week tirzepatide obesity trial; GI adverse events and discontinuation rates.
- 05 Rubino et al., Diabetes, Obesity and Metabolism, 2025 dom-pubs.onlinelibrary.wiley.com ↗Pooled SURMOUNT-1 to -4 GI tolerability and weight-reduction mediation analysis.
- 06 Gorgojo-Martinez et al., Journal of Clinical Medicine, 2023 pmc.ncbi.nlm.nih.gov ↗Multidisciplinary expert consensus on managing GI adverse events with GLP-1 receptor agonists.
- 07 Gentinetta et al., Diabetes, Metabolic Syndrome and Obesity, 2024 pmc.ncbi.nlm.nih.gov ↗Review of dietary management for GI symptoms in patients on GLP-1 receptor agonists.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
